Ketanserin in the treatment of systemic hypertension during and following coronary artery bypass surgery.
One of the most important problems during cardiac surgery is the prevention and treatment of hypertension, occurring in 40-60% of the patients following coronary artery bypass surgery (CABS). Hypertension should be avoided to prevent myocardial damage, neurologic complications, increased blood loss, and premature graft closure due to intimal damage. During and following cardiac surgery hypertension is routinely treated with vasodilating agents, which generally induce reflex tachycardia and increased intrapulmonary shunting. The results obtained with ketanserin, a specific S2-serotonergic receptor blocker with alpha 1-adrenergic receptor blocking properties, in the prevention and treatment of hypertension in patients undergoing cardiac surgery, are presented. Ketanserin effectively lowers blood pressure by decreasing systemic vascular resistance but does not completely prevent perioperative and postoperative hypertension when administered as a continuous infusion from the start of anesthesia. In contrast to sodium nitroprusside, ketanserin does not induce reflex tachycardia in the treatment of postoperative systemic hypertension following CABS. The compound improves diuresis and perfusion of the skin perioperatively. Ketanserin is devoid of rebound phenomena after its administration is stopped. It is postulated that the antihypertensive effect of ketanserin can be explained by its property of simultaneously blocking alpha 1-adrenergic and S2-serotonergic receptors.
van der Starre
P J
PJ
Department of Anesthesiology, Medical Center De Klokkenberg, Breda, The Netherlands.
Reneman
R S
RS
Scheijgrond
H W
HW
D001794:Blood Pressure; D002302:Cardiac Output; D001026:Coronary Artery Bypass; D005283:Fentanyl / Q000627:therapeutic use; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000517:prevention & control; D007362:Intensive Care Units; D007431:Intraoperative Complications / Q000188:drug therapy; D007650:Ketanserin / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000627:therapeutic use; D011183:Postoperative Complications / Q000188:drug therapy; D011651:Pulmonary Artery / Q000503:physiopathology; D012881:Skin Temperature; D014655:Vascular Resistance
D007650:Ketanserin; D005996:Nitroglycerin; D005283:Fentanyl